The biology of ovarian cancer: new opportunities for translation

By R. Bast, Bryan T. J. Hennessy, Gordon B. Mills. Nature Reviews. Cancer, 2009

1,413 citations recorded by the source corpus.

Over the past two decades, the 5-year survival for ovarian cancer patients has substantially improved owing to more effective surgery and treatment with empirically optimized combinations of cytotoxic drugs, but the overall cure rate remains approximately 30%. Many investigators think that further empirical trials using combinations of conventional agents are likely to produce only modest incremental improvements in outcome. Given the heterogeneity of this disease, increases in long-term survival might be achieved by translating recent insights at the molecular and cellular levels to personalize individual strategies for treatment and to optimize early detection.

Subfields: Pathology and Forensic Medicine, Reproductive Medicine

View Paper: https://www.semanticscholar.org/paper/9689242c78f8191fc6be96aeed3625f91c09522e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Pathology and Forensic Medicine

In Reproductive Medicine

Citations in the corpus

microRNAs in cancer (2013, background): “Mutational loss of p53 function is one of the most frequent genetic abnormalities in cancer: In ovarian cancer, it accounts for 60% to 80% of both sporadic and familial cases (96).”
Discovery of multi-dimensional modules by integrative analysis of cancer genomic data (2012, background): “carcinomas (56), and mutations in p53are the most common gene mutations in human cancer, including ovarian cancers (57).”
Repair Pathway Choices and Consequences at the Double-Strand Break (2015, positive): “Indeed, cancer cells often have at least one defective DNA repair pathway [102], and a significant proportion of cancers (especially breast and ovarian cancers) demonstrate defects in DNA repair genes, including many in the HR pathway [103].”
Efficient Dimensionality Reduction for High-Dimensional Network Estimation (2014, background): “Ovarian cancer is the 5th leading cause of cancer death among US women and has a 5-year survival rate of 30% (Bast et al., 2009).”
Integrated Genomic Analyses of Ovarian Carcinoma (2011, background): “Lawrence(3), Kristian Cibulskis(8), Andrey Sivachenko(3), Carrie Sougnez(72), Douglas Voet(3), Jane Wilkinson(73), Toby Bloom(74), Kristin Ardlie(3), Tim Fennell(75), Jennifer Baldwin(73), Stacey Gabriel(2), Eric S.”
Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer (2015, background): “by frequent genetic and epigenetic alterations of HR pathway genes, most commonly the BRCA1 and BRCA2 genes (16, 17).”